NCT00944905 (Clinical Trial / MDX-1203)

Study Title
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) (NCT00944905)

Trial Description
The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin’s lymphoma.

This trial is sponsored by Bristol-Myers Sqibb [1]

Study Data

  • Condition:
    • Renal Cell Carcinoma
    • Non-hodgkin’s Lymphoma
  • Interventions:
    • Drugs used in this trial
      • MDX-1203
  • Phase: I
  • Enrollment: 46
  • Start: July 2009
  • Completion: November 2012
  • Last verified: May 2013

Study Schematic 

Click here to Return to Drug map

Last Editorial review: July 10, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.